Quantcast

Selexis to Present at Cell Culture Engineering XIII

April 19, 2012

Selexis´ co-founder and scientific advisory board member, Nicolas Mermod, PhD, Professor of Biotechnology at Faculty of Biology and Medicine of the University of Lausanne, will present, “Engineering CHO Cells and Vectors for Improved Transgene Integration and Antibody Production.”

Geneva, Switzerland (PRWEB) April 19, 2012

Selexis SA announced today the Company´s co-founder will present data on the Company´s core technology at the 13th Annual Cell Culture Engineering conference being held April 22 — 27, 2012 in Scottsdale, Arizona, USA. Selexis´ co-founder and scientific advisory board member, Nicolas Mermod, PhD, Professor of Biotechnology at Faculty of Biology and Medicine of the University of Lausanne, will present, “Engineering CHO Cells and Vectors for Improved Transgene Integration and Antibody Production,” on Thursday, April 26 at 3:45 PM as part of the cell line development tract.

Additionally, A poster presentation entitled, “Combining Epigenetic Chromatin Regulatory Elements, Cell Line Engineering and Cell Culture Condition Optimization in a Comprehensive Platform for Enhanced Recombinant Protein Production,” is scheduled to be presented. The poster presentation will illustrate applying the Selexis SUREtechnology Platform as a new solution for more efficient identification of individual therapeutic protein candidates. The company´s CEO, Dr. Igor Fisch, will present the poster and will be available for questions.

Presentation Abstract

“Engineering CHO Cells and Vectors for Improved Transgene Integration and Antibody Production”

Incorporation of epigenetic regulatory DNA elements in expression vectors can prevent gene silencing and increase transcription rates. This has yielded stable and very high protein expression from CHO cells and increased therapeutic production in the bioreactor. Such progress have led to newly emerging bottlenecks encompassing transgene genomic integration, protein secretion and processing, and cell physiology. We have determined the genome sequence of CHO cells used for pharmaceutical production and of derived therapeutic producer clones. This has allowed transient cell engineering for increased genomic transgene integration by recombination and higher expression. Stable engineering of the cell secretion and processing pathways allowed for improved protein secretion and consistency. This presentation will thus illustrate how a systematic and multi-level approach can be used to improve the expression of pharmaceutical proteins.

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform is based on Selexis Genetic Elements — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform to be launched in 2012.

For more information:

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebantibody_potein_cell_line/selexis_CHO_cell/prweb9417607.htm


Source: prweb



comments powered by Disqus